MiniMed Group reported fiscal 2027 first-quarter revenue of $843 million, up 15.8% organically, and raised its full-year organic growth forecast to approximately 10.5%. Excluding the benefit of an extra fiscal week, growth was in the low double digits, compared with 8.7% in the prior quarter. U.S. revenue rose 13.1%, driven by the MiniMed Flex pump launch, which contributed to a more than 20% increase in new pumps sold and a 24% rise in new prescribers. International organic revenue grew 16.9%, with Western Europe up in the high teens. Adjusted EBITDA was $83 million, a margin of 9.9%, including impacts from accelerated investments and a foreign-exchange charge; excluding those, the margin would have been 12.2%. The company reaffirmed its 16% adjusted EBITDA margin target for the year and provided pipeline updates, including the Fit patch pump and Vivera closed-loop algorithm.
MiniMed Group, Inc. Common StockStrong Q1 revenue growth driven by MiniMed Flex pump launch, raising fiscal 2027 outlook.
Medtronic PLC